Proton Pump Inhibitors Long-term Use Does Not Lead to Higher Risk of Gastric Cancer, Study Reveals

A study has revealed that use of proton pump inhibitors or PPIs in the long term, as compared to histamine 2 receptor antagonists or H2Ras, does not lead to a higher risk of gastric cancer even in a high-risk region.

Photo: Proton Pump Inhibitor | InStyleHealth


According to researchers, “PPIs are commonly prescribed medications.” “Long-term use of PPIs has been suspected to have a provocative effect on gastric cancer.”

A population-based cohort study was carried out, to determine whether PPI vs H2RA use associated with the risk of gastric cancer in a region where the risk was high, with the use of the Korean National Health Insurance Services Database.

Experts included participants with first prescription of PPIs and H2Ras with normal esophagogastroduodenoscopy finding from 2004 through 2005, among whom half or 50% were sampled in a systematically stratified random way.

There was a total of 122,118 volunteers on PPIs or H2Ras used the medication more than the cumulative defined daily dose of 180 days. The users were then followed from long-term use threshold until gastric cancer, death from non-gastric cancer cause, gastric surgery, or study end (December 2017).

Following the calculation for propensity score weights, 39,799 PPI and 38,967 H2RA users were included. Of the new users, 411 and 397 cases of incident gastric cancer were identified from 182,643 and 178,846 person-years of follow-up observation, correspondingly.

Notably, PPI users did not experience a significantly increased incidence of gastric cancer relative to H2RA users. No between-group difference was also observed in gastric cancer incidence in sensitivity analyses.

 

Source: Am J Gastroenterol 2021;116:1211-1219

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post